Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery.

Nathan PJ, Phan KL, Harmer CJ, Mehta MA, Bullmore ET.

Curr Opin Pharmacol. 2014 Feb;14:54-61. doi: 10.1016/j.coph.2013.11.009. Epub 2013 Dec 8. Review.

PMID:
24565013
2.

The role of imaging in proof of concept for CNS drug discovery and development.

Wong DF, Tauscher J, Gründer G.

Neuropsychopharmacology. 2009 Jan;34(1):187-203. doi: 10.1038/npp.2008.166. Epub 2008 Oct 8. Review.

3.

Use of non-invasive neuroradiological methods in research of psychoactive drugs.

Henigsberg N, Kovacić Z, Kalember P.

Psychiatr Danub. 2007 Sep;19(3):234-7.

PMID:
17914326
4.

Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.

Bifone A, Gozzi A.

Expert Opin Drug Discov. 2012 Nov;7(11):1071-82. doi: 10.1517/17460441.2012.724057. Epub 2012 Sep 13. Review.

PMID:
22971143
5.

Role of functional magnetic resonance imaging in drug discovery.

Paulus MP, Stein MB.

Neuropsychol Rev. 2007 Jun;17(2):179-88. Epub 2007 Apr 10. Review.

6.

Use of functional imaging across clinical phases in CNS drug development.

Borsook D, Becerra L, Fava M.

Transl Psychiatry. 2013 Jul 16;3:e282. doi: 10.1038/tp.2013.43.

7.

Using NMR approaches to drive the search for new CNS therapeutics.

Borsook D, Becerra L.

Curr Opin Investig Drugs. 2010 Jul;11(7):771-8. Review.

8.

Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery.

Li J, Schwarz AJ, Gilmour G.

Curr Top Behav Neurosci. 2016;28:397-421. doi: 10.1007/7854_2016_1. Review.

PMID:
27023366
9.

The role of fMRI in drug discovery.

Wise RG, Tracey I.

J Magn Reson Imaging. 2006 Jun;23(6):862-76. Review.

PMID:
16649197
10.

What is the value of human FMRI in CNS drug development?

Wise RG, Preston C.

Drug Discov Today. 2010 Nov;15(21-22):973-80. doi: 10.1016/j.drudis.2010.08.016. Epub 2010 Sep 15. Review.

PMID:
20813202
11.

Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift.

Fu CH, Costafreda SG.

Can J Psychiatry. 2013 Sep;58(9):499-508. Review.

PMID:
24099497
12.

Drug discovery in psychiatric illness: mining for gold.

Elmer GI, Kafkafi N.

Schizophr Bull. 2009 Mar;35(2):287-92. doi: 10.1093/schbul/sbn194. Epub 2009 Mar 18.

13.

Applications of functional magnetic resonance imaging in psychiatry.

Mitterschiffthaler MT, Ettinger U, Mehta MA, Mataix-Cols D, Williams SC.

J Magn Reson Imaging. 2006 Jun;23(6):851-61. Review.

PMID:
16652410
14.

Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation.

Hellyer S, Leach K, Gregory KJ.

Curr Opin Pharmacol. 2017 Feb;32:49-55. doi: 10.1016/j.coph.2016.10.007. Epub 2016 Nov 11. Review.

PMID:
27842256
15.

Target identification for CNS diseases by transcriptional profiling.

Altar CA, Vawter MP, Ginsberg SD.

Neuropsychopharmacology. 2009 Jan;34(1):18-54. doi: 10.1038/npp.2008.172. Epub 2008 Oct 15. Review.

16.

A Window into the Brain: Advances in Psychiatric fMRI.

Zhan X, Yu R.

Biomed Res Int. 2015;2015:542467. doi: 10.1155/2015/542467. Epub 2015 Aug 27. Review.

17.

Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.

Cole PE, Schwarz AJ, Schmidt ME.

Clin Pharmacol Ther. 2012 Feb;91(2):315-20. doi: 10.1038/clpt.2011.286. Epub 2012 Jan 4. Review.

PMID:
22218072
18.

Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging.

Callicott JH, Weinberger DR.

Eur J Radiol. 1999 May;30(2):95-104. Review.

PMID:
10401590
19.

A role for fMRI in optimizing CNS drug development.

Borsook D, Becerra L, Hargreaves R.

Nat Rev Drug Discov. 2006 May;5(5):411-24. Review.

PMID:
16604100
20.

[Contribute of functional magnetic resonance imaging to the understanding of psychiatric disorders].

Höller Y, Kronbichler M, Zeller A, Klein S, Hinterhuber H, Golaszewski S, Ladurner G.

Neuropsychiatr. 2009;23(2):84-90. Review. German.

PMID:
19573501

Supplemental Content

Support Center